This is an observational study, called a registry, for people with AQP4+ NMOSD (Neuromyelitis Optica Spectrum Disorder, a rare autoimmune disease affecting the brain and spinal cord). It's collecting information on how Alexion C5 inhibitor therapies (C5IT) affect patients in the real world. Researchers will look at your medical history and how often you experience relapses (Annualized Relapse Rate or ARR) over approximately five years. They will also gather information on your quality of life. To join, you must be at least 18 years old, have a confirmed diagnosis of AQP4+ NMOSD, and already be receiving an Alexion C5 inhibitor therapy for relapse prevention. The current status of this study is unclear.

Study design

This is an observational registry study with a planned enrollment of 122 participants. It is designed to collect real-world data on patients already receiving treatment.

What's involved

At enrollment, your past medical records and AQP4+ NMOSD treatment history from one year before starting ALXN-C5IT will be reviewed. Data collection will continue for approximately five years from the last participant's enrollment.

Compensation

Not stated in the trial record.

Follow-up

Participants' data will be collected for approximately five years from the day the last participant is enrolled.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.